| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | ADVANCED SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Biosignal Research Center, Kobe University, Kobe 657-8501, Japa
2 CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan
3 Department of Geriatric Medicine, Kobe University School of Medicine, Kobe 650-0017, Japan
4 Department of Molecular Biology and the Diabetes Unit, Medical Services, Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114, USA
The mammalian target of rapamycin (mTOR) is a Ser/Thr protein kinase that plays a crucial role in a nutrient-sensitive signalling pathway that regulates cell growth. TOR signalling is potently inhibited by rapamycin, through the direct binding of a FK506-binding protein 12 (FKBP12)/rapamycin complex to the TOR FRB domain, a segment amino terminal to the kinase catalytic domain. The molecular basis for the inhibitory action of FKBP12/rapamycin remains uncertain. Raptor (regulatory associated protein of mTOR) is a recently identified mTOR binding partner that is essential for mTOR signalling in vivo, and whose binding to mTOR is critical for mTOR-catalysed substrate phosphorylation in vitro. Here we investigated the stability of endogenous mTOR/raptor complex in response to rapamycin in vivo, and to the direct addition of a FKBP12/rapamycin complex in vitro. Rapamycin diminished the recovery of endogenous raptor with endogenous or recombinant mTOR in vivo; this inhibition required the ability of mTOR to bind the FKBP12/rapamycin complex, but was independent of mTOR kinase activity. Rapamycin, in the presence of FKBP12, inhibited the association of raptor with mTOR directly in vitro, and concomitantly reduced the mTOR-catalysed phosphorylation of raptor-dependent, but not raptor-independent substrates; mTOR autophosphorylation was unaltered. These observations indicate that rapamycin inhibits mTOR function, at least in part, by inhibiting the interaction of raptor with mTOR; this action uncouples mTOR from its substrates, and inhibits mTOR signalling without altering mTOR's intrinsic catalytic activity.
* Correspondence: E-mail: yonezawa{at}kobe-u.ac.jp
This article has been cited by other articles:
|
|
 |
|
  T. Sato, A. Nakashima, L. Guo, and F. Tamanoi Specific Activation of mTORC1 by Rheb G-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein J. Biol. Chem., May 8, 2009; 284(19): 12783 - 12791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. KIM, K. ZUKOWSKI, and R. F. NOVAK Rapamycin Effects on mTOR Signaling in Benign, Premalignant and Malignant Human Breast Epithelial Cells Anticancer Res, April 1, 2009; 29(4): 1143 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Avruch, X. Long, S. Ortiz-Vega, J. Rapley, A. Papageorgiou, and N. Dai Amino acid regulation of TOR complex 1 Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E592 - E602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Drummond, C. S. Fry, E. L. Glynn, H. C. Dreyer, S. Dhanani, K. L. Timmerman, E. Volpi, and B. B. Rasmussen Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis J. Physiol., April 1, 2009; 587(7): 1535 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Weichhart and M D Saemann The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii70 - iii74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohne, T. Takahara, R. Hatakeyama, T. Matsuzaki, M. Noda, N. Mizushima, and T. Maeda Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin J. Biol. Chem., November 14, 2008; 283(46): 31861 - 31870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Shor, W.-G. Zhang, L. Toral-Barza, J. Lucas, R. T. Abraham, J. J. Gibbons, and K. Yu A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis Cancer Res., April 15, 2008; 68(8): 2934 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kong, S. Banerjee, W. Huang, Y. Li, Z. Wang, H.-R. C. Kim, and F. H. Sarkar Mammalian Target of Rapamycin Repression by 3,3'-Diindolylmethane Inhibits Invasion and Angiogenesis in Platelet-Derived Growth Factor-D-Overexpressing PC3 Cells Cancer Res., March 15, 2008; 68(6): 1927 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Qian, H. Du, B. F. King, S. Kumar, P. G. Dean, F. G. Cosio, and V. E. Torres Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients J. Am. Soc. Nephrol., March 1, 2008; 19(3): 631 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli, P. Maione, and A. Rossi The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer Oncologist, February 1, 2008; 13(2): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Suryawan, R. A. Orellana, H. V. Nguyen, A. S. Jeyapalan, J. R. Fleming, and T. A. Davis Activation by insulin and amino acids of signaling components leading to translation initiation in skeletal muscle of neonatal pigs is developmentally regulated Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1597 - E1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Li, M. Petrimpol, K. D. Molle, M. N. Hall, E. J. Battegay, and R. Humar Hypoxia-Induced Endothelial Proliferation Requires Both mTORC1 and mTORC2 Circ. Res., January 5, 2007; 100(1): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takahara, K. Hara, K. Yonezawa, H. Sorimachi, and T. Maeda Nutrient-dependent Multimerization of the Mammalian Target of Rapamycin through the N-terminal HEAT Repeat Region J. Biol. Chem., September 29, 2006; 281(39): 28605 - 28614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Williamson, D. R. Bolster, S. R. Kimball, and L. S. Jefferson Time course changes in signaling pathways and protein synthesis in C2C12 myotubes following AMPK activation by AICAR. Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E80 - E89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Vega, L. J. Medeiros, V. Leventaki, C. Atwell, J. H. Cho-Vega, L. Tian, F.-X. Claret, and G. Z. Rassidakis Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. Cancer Res., July 1, 2006; 66(13): 6589 - 6597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eguchi, C. Tokunaga, S. Hidayat, N. Oshiro, K.-i. Yoshino, U. Kikkawa, and K. Yonezawa Different roles for the TOS and RAIP motifs of the translational regulator protein 4E-BP1 in the association with raptor and phosphorylation by mTOR in the regulation of cell size. Genes Cells, July 1, 2006; 11(7): 757 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Mahfouz, S. Kim, A. J. Delauney, and D. P. S. Verma Arabidopsis TARGET OF RAPAMYCIN Interacts with RAPTOR, Which Regulates the Activity of S6 Kinase in Response to Osmotic Stress Signals PLANT CELL, February 1, 2006; 18(2): 477 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tzatsos and K. V. Kandror Nutrients Suppress Phosphatidylinositol 3-Kinase/Akt Signaling via Raptor-Dependent mTOR-Mediated Insulin Receptor Substrate 1 Phosphorylation Mol. Cell. Biol., January 1, 2006; 26(1): 63 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ohji, S. Hidayat, A. Nakashima, C. Tokunaga, N. Oshiro, K.-i. Yoshino, K. Yokono, U. Kikkawa, and K. Yonezawa Suppression of the mTOR-Raptor Signaling Pathway by the Inhibitor of Heat Shock Protein 90 Geldanamycin J. Biochem., January 1, 2006; 139(1): 129 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Kimball and L. S. Jefferson Signaling Pathways and Molecular Mechanisms through which Branched-Chain Amino Acids Mediate Translational Control of Protein Synthesis J. Nutr., January 1, 2006; 136(1): 227S - 231S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paglin, N.-Y. Lee, C. Nakar, M. Fitzgerald, J. Plotkin, B. Deuel, N. Hackett, M. McMahill, E. Sphicas, N. Lampen, et al. Rapamycin-Sensitive Pathway Regulates Mitochondrial Membrane Potential, Autophagy, and Survival in Irradiated MCF-7 Cells Cancer Res., December 1, 2005; 65(23): 11061 - 11070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Ali and D. M. Sabatini Structure of S6 Kinase 1 Determines whether Raptor-mTOR or Rictor-mTOR Phosphorylates Its Hydrophobic Motif Site J. Biol. Chem., May 20, 2005; 280(20): 19445 - 19448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, A. Beugnet, M. Murakami, S. Yamanaka, and C. G. Proud Distinct Signaling Events Downstream of mTOR Cooperate To Mediate the Effects of Amino Acids and Insulin on Initiation Factor 4E-Binding Proteins Mol. Cell. Biol., April 1, 2005; 25(7): 2558 - 2572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mothe-Satney, N. Gautier, C. Hinault, J. C. Lawrence Jr., and E. Van Obberghen In Rat Hepatocytes Glucagon Increases Mammalian Target of Rapamycin Phosphorylation on Serine 2448 but Antagonizes the Phosphorylation of Its Downstream Targets Induced by Insulin and Amino Acids J. Biol. Chem., October 8, 2004; 279(41): 42628 - 42637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hay and N. Sonenberg Upstream and downstream of mTOR Genes & Dev., August 15, 2004; 18(16): 1926 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Erratum Genes Cells, May 1, 2004; 9(5): 497 - 497. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | ADVANCED SEARCH | TABLE OF CONTENTS |
